Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D brings $34.5mm to Avid Radiopharmaceuticals

Executive Summary

Molecular imaging company Avid Radiopharmaceuticals brought in $34.5mm via its Series D round led by Alta Partners, which adds a board member. Joining first-timer Alta were returning shareholders AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group, and BioAdvance. Funds will be used to finish developing and launch the company's amyloid imaging agent 18FAV45 for Alzheimer's disease, and for ongoing Phase II trials of 18FAV133 for Parkinson's.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies